Press Releases
Endonovo Therapeutics Signs Distribution Agreement For National Distribution of Sofpulse® Electroceutical™ System
Download PDF
LOS ANGELES, CA, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"
, a commercial-stage developer of Electroceutical™ Therapies, today announced a distribution agreement with Magniant, LLC (“Magniant”) for the distribution of SofPulse®, its non-invasive Electroceutical™ Therapy for post-operative pain relief and reduction of swelling. The agreement with Magniant includes sales, marketing and distribution targeting the VA, DOD, Indian Health Services, Long Term Care Institutions, Pain Clinics, Wound Clinics and Private Practices among physicians.
Alan Collier, Endonovo Chief Executive Officer, stated, “We are thrilled to partner with Magniant, an established firm with significant health industry experience, in depth knowledge of product launches and, more importantly, relationships with healthcare professionals and facilities throughout the United States. In addition to a professional, accountable team of commission-based representatives, Magniant delivers meaningful senior leadership in the areas of Supply Chain, FP&A, Operations and Logistics, Marketing, and Clinical Business Development. I welcome the opportunity of working with their team and expanding our Sofpulse device on a national level.”
“Expanding our portfolio with the addition of SofPulse® is extremely exciting for us. SofPulse® is an evolutionary technology and we look forward to offering this simple, effective and non-invasive therapy to help reduce swelling and speed up the natural recovery process to our customers across the healthcare continuum,” said Robert Crousore, President of Magniant.
Endonovo will retain responsibility for product development, regulatory approval, quality management, and manufacturing while Magniant will be responsible for sales, marketing, customer support and distribution activities.
About Magniant, LLC
A national contract sales and marketing firm specializing in the healthcare continuum. Magniant represents medical technology manufacturers and drives revenue growth strategies and top-line results. Magniant specializes in supporting innovative technologies and clinical solutions into the acute care market, long term care, physician, homecare, and the government healthcare system. The leadership team’s experience and most importantly, strong relationships, make Magniant a unique and powerful partner to drive measurable results for medical manufacturers. www.magniant.com
About Endonovo Therapeutics
Endonovo Therapeutics, Inc. is a commercial-stage developer of non-invasive wearable Electroceuticals™ Therapies. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals™ Therapies addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) Disorders, including traumatic brain injury (TBI), acute concussions, post-concussion syndrome and multiple sclerosis. The Company's non-invasive Electroceutical™ System device, SofPulse®, using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative pain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company's current portfolio of pre-clinical stage Electroceuticals™ addresses chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke. The Company's non-invasive, wearable Electroceuticals™ work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur. www.endonovo.com
Safe Harbor Statement
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.
Investor Relations Contact:
Endonovo Therapeutics, Inc.
Mr. Andrew Barwicki
516-662-9461
Andrew@barwicki.com
www.endonovo.com
Primary Logo
Source: Endonovo Therapeutics, Inc.
Released August 14, 2018
Endonovo Therapeutics Signs Distribution Agreement For National Distribution of Sofpulse® Electroceutical™ System
Download PDF
LOS ANGELES, CA, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"
, a commercial-stage developer of Electroceutical™ Therapies, today announced a distribution agreement with Magniant, LLC (“Magniant”) for the distribution of SofPulse®, its non-invasive Electroceutical™ Therapy for post-operative pain relief and reduction of swelling. The agreement with Magniant includes sales, marketing and distribution targeting the VA, DOD, Indian Health Services, Long Term Care Institutions, Pain Clinics, Wound Clinics and Private Practices among physicians. Alan Collier, Endonovo Chief Executive Officer, stated, “We are thrilled to partner with Magniant, an established firm with significant health industry experience, in depth knowledge of product launches and, more importantly, relationships with healthcare professionals and facilities throughout the United States. In addition to a professional, accountable team of commission-based representatives, Magniant delivers meaningful senior leadership in the areas of Supply Chain, FP&A, Operations and Logistics, Marketing, and Clinical Business Development. I welcome the opportunity of working with their team and expanding our Sofpulse device on a national level.”
“Expanding our portfolio with the addition of SofPulse® is extremely exciting for us. SofPulse® is an evolutionary technology and we look forward to offering this simple, effective and non-invasive therapy to help reduce swelling and speed up the natural recovery process to our customers across the healthcare continuum,” said Robert Crousore, President of Magniant.
Endonovo will retain responsibility for product development, regulatory approval, quality management, and manufacturing while Magniant will be responsible for sales, marketing, customer support and distribution activities.
About Magniant, LLC
A national contract sales and marketing firm specializing in the healthcare continuum. Magniant represents medical technology manufacturers and drives revenue growth strategies and top-line results. Magniant specializes in supporting innovative technologies and clinical solutions into the acute care market, long term care, physician, homecare, and the government healthcare system. The leadership team’s experience and most importantly, strong relationships, make Magniant a unique and powerful partner to drive measurable results for medical manufacturers. www.magniant.com
About Endonovo Therapeutics
Endonovo Therapeutics, Inc. is a commercial-stage developer of non-invasive wearable Electroceuticals™ Therapies. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals™ Therapies addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) Disorders, including traumatic brain injury (TBI), acute concussions, post-concussion syndrome and multiple sclerosis. The Company's non-invasive Electroceutical™ System device, SofPulse®, using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative pain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company's current portfolio of pre-clinical stage Electroceuticals™ addresses chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke. The Company's non-invasive, wearable Electroceuticals™ work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur. www.endonovo.com
Safe Harbor Statement
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.
Investor Relations Contact:
Endonovo Therapeutics, Inc.
Mr. Andrew Barwicki
516-662-9461
Andrew@barwicki.com
www.endonovo.com
Primary Logo
Source: Endonovo Therapeutics, Inc.
Released August 14, 2018
